UMIN ID: UMIN000002619
Registered date:31/03/2010
Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Thymoma/Thymic carcinoma |
| Date of first enrollment | 2008/09/01 |
| Target sample size | 40 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Amrubicin and carboplatin |
Outcome(s)
| Primary Outcome | Response rate |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman |
Related Information
| Primary Sponsor | Tohoku University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Tohoku University Hospital |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Akira Inoue |
| Address | 1-1, Seiryocho, Aobaku, Sendai |
| Telephone | +81-22-717-8539 |
| akinoue@idac.tohoku.ac.jp | |
| Affiliation | Tohoku University Hospital Department of Respiratory Medicine |
| scientific contact | |
| Name | Akira Inoue |
| Address | 1-1, Seiryomachi, Aobaku, Sendai |
| Telephone | +81-22-717-8539 |
| akinoue@idac.tohoku.ac.jp | |
| Affiliation | Tohoku University Hospital Department of Respiratory Medicine |